School of Medicine, Vita-Salute San Raffaele University, Milan, Italy -
Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy -
Panminerva Med. 2022 Jun;64(2):244-252. doi: 10.23736/S0031-0808.20.04168-3. Epub 2020 Oct 19.
Biobanks are imperative infrastructures, particularly during outbreaks, when there is an obligation to acquire and share knowledge as quick as possible to allow for implementation of science-based preventive, diagnostic, prognostic, and therapeutic strategies.
We established a COVID-19 biobank with the aim of collecting high-quality and well-annotated human biospecimens, in the effort to understand the pathogenic mechanisms underlying COVID-19 and identify therapeutic targets (COVID-BioB, NCT04318366). Here we describe our experience and briefly review the characteristics of the biobanks for COVID-19 that have been so far established.
A total of 46,677 samples have been collected from 913 participants (63.3% males, median [IQR] age 62.2 [51.2-74.0] years) since the beginning of the program. Most patients (66.9%) had been admitted to hospital for COVID-19, with a median length of stay of 15.0 (9.0-27.0) days. A minority of patients (13.3% of the total) had been admitted for other reasons and subsequently tested positive for SARS-CoV-2. The remainder were managed at home after being seen at the Emergency Department.
Having a solid research infrastructure already in place, along with flexibility and adaptability to new requirements, allowed for the quick building of a COVID-19 biobank that will help expand and share the knowledge of SARS-CoV-2.
生物库是必要的基础设施，尤其是在疫情爆发期间，有义务尽快获取和分享知识，以便实施基于科学的预防、诊断、预后和治疗策略。
我们建立了一个 COVID-19 生物库，旨在收集高质量和充分注释的人体生物标本，以努力了解 COVID-19 的发病机制并确定治疗靶点（COVID-BioB，NCT04318366）。在这里，我们描述了我们的经验，并简要回顾了迄今为止建立的 COVID-19 生物库的特点。
自项目启动以来，已从 913 名参与者（63.3%为男性，中位[IQR]年龄 62.2[51.2-74.0]岁）中收集了 46677 份样本。大多数患者（66.9%）因 COVID-19 住院，中位住院时间为 15.0（9.0-27.0）天。少数患者（占总数的 13.3%）因其他原因住院，随后 SARS-CoV-2 检测呈阳性。其余患者在急诊科就诊后在家中接受治疗。
拥有坚实的研究基础设施，以及对新需求的灵活性和适应性，使我们能够快速建立一个 COVID-19 生物库，这将有助于扩大和分享 SARS-CoV-2 的知识。
